Concentric Medical Announces Initiation of the First Stentriever(TM) Study in Europe

MOUNTAIN VIEW, California, September 30, 2010 - Concentric Medical, Inc., the global leader in acute ischemic stroke
intervention, today announced the start of the TREVO Study. The first
patients were enrolled and successfully treated at the Hospital Clinic de
Barcelona by the Neuroradiology team of Drs. Juan Macho and Jordi Blasco.

The TREVO Study (Thrombectomy REvascularization of large Vessel
Occlusions in acute ischemic stroke) is the first to evaluate Stentriever(TM)
technology in a European, multicenter, prospective trial. TREVO is designed
to assess the ability of the Trevo System to remove the blood clots that
cause strokes and to restore blood flow to the brain. Additionally,
functional outcomes at 90 days will be collected. Professor Olav Jansen, Head
of Interventional Neuroradiology at Universitatsklinikum Schleswig-Holstein,
and Professor Nils Wahlgren, Professor of Neurology at Karolinska University
Hospital, are co-Principal Investigators of the Study.

Following the treatment of the first patients enrolled into the TREVO
Study, Juan Macho, MD, PhD. said, "The Trevo(TM) System represents a new
treatment option for ischemic stroke patients. It is easy and fast to use and
this is essential in the acute stroke setting because a patient's brain is at
risk. I have found the Trevo to be remarkably effective."

Maria Sainz, President and CEO of Concentric Medical, commented on the
importance of the study, "Treatment of the first patients in the TREVO Study
is a key milestone that demonstrates Concentric's continued commitment to
advancing acute stroke intervention. The TREVO Study will provide prospective
multi-center clinical evidence that will accelerate adoption of this new
technology for acute ischemic stroke patients." She added, "European
physicians have been pioneers in investigating the clinical possibilities of
stentriever technology, so we are excited to conduct our first study with our
newest device, Trevo, in Europe."

About Concentric Medical

Concentric Medical is located in Mountain View, California and is the
global leader in the development of endovascular devices for revascularizing
stroke patients. The company manufactures and markets solutions for ischemic
stroke: minimally invasive devices that are delivered into the brain to
restore blood flow by removing blood clots that cause ischemic stroke.
Concentric Medical's devices are available in over 500 leading stroke centers
around the world, and have been the subject of several clinical studies in
which over 1,300 patients have been enrolled. For more information about
Concentric Medical, please visit www.concentric-medical.com.

About the Trevo System

The Trevo(TM) System is an innovative, high-performing, easy-to-use
thrombus retrieval system that utilizes Stentriever(TM) technology and
creates a new generation of retrieval devices to remove clot in ischemic
stroke patients. Concentric Medical is the pioneer in developing devices for
ischemic stroke intervention. Since 2002, Concentric Medical's devices have
been used in thousands of stroke patients worldwide. This experience has been
incorporated into the design of the Trevo System to make thrombus removal an
easier, faster and more predictable procedure. The new Trevo System combined
with the Merci(R) portfolio of products further strengthens Concentric
Medical's position as the global leader in acute ischemic stroke
intervention.

About Acute Ischemic Stroke

Stroke is the third leading cause of death in the developed world and the
leading cause of serious long-term disability. Ischemic stroke represents
over 85% of strokes and occurs when a blockage or clot develops in one of the
arteries supplying blood to the brain. CE mark for the Merci Retriever was
first obtained in 2002. In 2004 the FDA cleared Concentric Medical's Merci
Retriever(R) for use in patients who are ineligible for IV-tPA or who fail to
respond to IV-tPA therapy. This pioneering device creates a departure from
the historic method of caring for stroke patients and offers physicians and
patients a long-awaited option for stroke intervention.

    Media Contact:
    +1-650-938-2100
    strokeinfo@concentric-medical.com

Concentric Medical, Inc., +1-650-938-2100, strokeinfo at concentric-medical.com